Congrats Array Biopharma on continued excellent data on its colorectal cancer (CRC) study of patients with BRAF V600E mutations with the triple therapy - Cetuximab, Array's BRAF inhibitor Bini and Array's BRAF inhibitor Enco. Overall survival not reached at 12.6 months vs. historical overall survival in this population of less than 8 months, and 48% ORR (3 CRs) vs. 16% ORR with competitive VIC therapy. Image shows best patient tumor measurements in this triplet vs. historical treatment (inset). Looking forward to PDUFA decisions on ARRY Bini and Enco in melanoma in coming days.
